#USA #Cambridge #Leap Therapeutics #ESMO Congress #DKK1 antibody

Leap Therapeutics to Present Final Clinical Data

Leap Therapeutics, Inc. is gearing up for an exciting presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025. The biotechnology company, recognized for its work in targeted and immuno-oncology therapeutics, will unveil the final results from Part B of the DeFianCe study, a significant Phase 2 clinical trial focusing on their innovative treatment approach for advanced microsatellite stable (MSS) colorectal cancer (CRC).

Overview of the DeFianCe Study

The DeFianCe study (NCT05480306) evaluates the efficacy of sirexatamab, an anti-DKK1 monoclonal antibody, when combined with bevacizumab and standard chemotherapy. This trial targets patients who have experienced one prior systemic therapy for their advanced disease. This combination aims to enhance treatment outcomes by leveraging the unique mechanisms of action of both sirexatamab and bevacizumab.

Upcoming Presentation at ESMO

According to the announcement from Leap Therapeutics, the pivotal results will be presented during a Mini Oral Session at the ESMO Congress, scheduled to take place from October 17-21, 2025, in Berlin, Germany. The session is titled “DeFianCe Trial: A Randomized Phase 2 Trial of Sirexatamab Plus Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy as Second-Line Therapy in Advanced MSS Colorectal Cancer.”

• - Presenter: Dr. Zev A. Wainberg, Professor of Medicine and Co-Director of the GI Oncology Program at UCLA
• - Session Details:

- Date and Time: Sunday, October 19, 2025, at 4:05 PM CEST
- Location: Cologne Auditorium – CityCube A
- Abstract Number: LBA34

Importance of the Findings

The final clinical data set to be discussed at ESMO is crucial both for the ongoing development of sirexatamab and for the wider oncology community. With colorectal cancer being one of the leading causes of cancer-related mortality, advancements in treatment options are urgently needed. This trial represents a potential breakthrough in second-line therapies for patients with MSS CRC, who often face limited options post-first-line treatment.

Leap Therapeutics: A Focus on Innovation

Leap Therapeutics continues to be at the forefront of innovative treatment:

• - Their pipeline includes not only sirexatamab but also FL-501, targeting the growth and differentiation factor 15 (GDF-15) protein.
• - Through continuous research and clinical trials, Leap aims to enhance patient outcomes in cancer treatments, echoing their commitment to fight against cancer.

Looking Ahead

With the imminent ESMO presentation, all eyes are on Leap Therapeutics as they prepare to share their findings with the international medical community. Each step in the clinical research journey leaves an indelible mark on how colorectal cancer may be treated in the future. The outcome of the DeFianCe study could expand the therapeutic arsenal available to oncologists, offering hope to patients facing advanced CRC.

To keep updated on Leap Therapeutics and their work, visit Leap Therapeutics Official Site or check their public filings available via the SEC. Catching the presentation at ESMO will undoubtedly be a highlight in the ongoing quest for advancements in cancer treatment.